BioSpace News Archive

Colossal Biosciences, the world’s first de-extinction company, and BioRescue, a consortium initiating and leading the scientific rescue mission of the northern white rhino employing advanced assisted reproduction technologies and stem cell associated techniques, have teamed up to save the northern white rhino from extinction.

CureDuchenne, a leading nonprofit organization dedicated to advancing research and improving the lives of individuals affected by Duchenne muscular dystrophy, is proud to announce the launch of the CureDuchenne Caregiver Course.

Atamyo Therapeutics announced the filing of a Clinical Trial Application in Europe for ATA-200, its gene therapy targeting γ-sarcoglycan related limb-girdle muscular dystrophy Type 2C/R5.

Perosphere Technologies has announced the receipt of two prestigious federal grants: a Direct Phase II Small Business Innovation Research grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health, and a subaward through an Atlanta Center for Microsystems Engineered Point-of-Care Technologies Center Grant, funded by the National Institute of Biomedical Imaging and Bioengineering.

Drug Farm, a clinical-stage biopharmaceutical company, announced that the first subject in the Phase 1 clinical trial evaluating DF-003 in healthy volunteers has been dosed.

BeiGene, Ltd. announced that the European Commission has approved TEVIMBRA® as monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Magnet Biomedicine, a biotechnology company advancing molecular glue discovery with rational selection and design, announced a $50 million Series A financing co-led by founding and initial investor, Newpath Partners, and ARCH Venture Partners.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced it will present at the Cantor Global Healthcare Conference on Wednesday, September 27th, 2023 at 4:10 p.m. ET in New York, NY.

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration has accepted and granted priority review for a supplemental new drug application seeking approval for WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, for the treatment of adult patients with advanced renal cell carcinoma following immune checkpoint and anti-angiogenic therapies.

Pharvaris, a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, will attend the 2023 Cantor Global Healthcare Conference, taking place in New York from September 26-28, 2023.